Thursday
Sep212017

SPARCtool updated to version 8.2 

version 8.2 release notes (Sept 2017)

www.sparctool.com 

SPARCtool

  • Removed the US-specific edoxaban renal warnings as monographs differ on this worldwide. Replaced it with the same renal function warning as other NOACs, which is consistent with all edoxaban monographs.
  • Added “Text for EMR” box for be cut-and-paste into EMR. Thank you, Mark McConnell, for this suggestion.

SPARCmobile

  • Removed the US-specific edoxaban renal warnings as monographs differ on this worldwide. Replaced it with the same renal function warning as other NOACs, which is consistent with all edoxaban monographs.
  • added an estimate for “Patient’s annual risk of stroke or TIA with no therapy if they did NOT have AF (for comparison):” based on Mitchell LB, Southern DA, Galbraith D, et al. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart. 2014;100(19):1524–1530. doi:10.1136/heartjnl–2013–305303. CHA2DS2-VASc preducts stroke in non-AF patients simiarly well to AF patients. The risk estimates are much lower for non-AF patients, of course. This is added to SPARCtool based on feedback that it is valuable for patients to see how much higher their stroke risk is because of AF vs. without it.
Friday
Apr072017

Bleeding - The Long & Short of It - Best Science Medicine Course 2017

Sunday
Oct272013

Know Your Birth Control Rights

Updated! 

Friday
Mar082013

SPARCtool Updated

version 6.21 release notes

SPARCmobile

  • updated the disclaimer
  • fixed truncated renal dysfunction warning for new OACs on iPhone and increased visibility of warnings.
  • changed text of the warnings to “RENAL FUNCTION WARNING: Consult product monograph.” - dosage adjustment thresholds and stragtegies are evolving, so no specific advice is offered in the SPARCtool.
  • lightened most of the fill colors
  • updated dabigatran 150mg thromboembolism risk with updated RE-LY data (updated RR 0.66 −-> 0.65, RRR vs. warfarin from 78% to 79%) [Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly Identified Events in the RE-LY Trial. N Engl J Med 2010;363:1875–6.]
  • corrected major bleeding risk of ASA+clopidogrel to be the same as warfarin based on ACTIVE-W.
  • added tabular view of the risks

SPARCtool

  • updated the disclaimer
  • changed text of the warnings to "WARNING: may be contraindicated or require dosage reduction depending on degree of renal dysfunction. Consult your country's monograph."
  • dosage adjustment thresholds and stragtegies are evolving, so no specific advice is offered in the SPARCtool.
  • lightened most of the fill colors
  • updated dabigatran 150mg thromboembolism risk with updated RE-LY data (updated RR 0.66 −-> 0.65, RRR vs. warfarin from 78% to 79%) [Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly Identified Events in the RE-LY Trial. N Engl J Med 2010;363:1875–6.]
  • corrected major bleeding risk of ASA+clopidogrel to be the same as warfarin based on ACTIVE-W.
  • added tabular view of the risks
  • added graphical representation of the risks (requires Adobe Flash to view)
Thursday
Nov292012

SPARCtool Updated to version 6.1

Release Notes

version 6.1 release notes

  • edited mobile/standard links to map to new site www.sparctool.com
  • edited sparcnotes links to map to new site and completely rewrote and reorganized SPARCtool Notes
  • fixed date field width on regular version
  • updated CHADS2 and CHA2DS2-VASc risk estimates to use BMJ 2011;342:d124, 10 year followup estimates.
  • upated all the CHADS2 risk descriptors to match the CHADS-VASc one based on BMJ 2011;342:d124, which is paraphrased as "ischemic stroke+thromboembolism"
  • updated warfarin population average major bleeding risk from 2.6 to 3.8%/year based on CMAJ November 26, 2012 cmaj.121218
  • add a reference for bleeding risk CPR vs. clinician judgement
  • added a warning for dabigatran, rivaroxaban, apixaban if "abnormal renal function" is checked in HAS-BLED
  • added a disclaimer to top of both tools